Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis

Published:2017-08-18 Issue:40 Volume:8 Page:68890-68898
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Omae Kenji¹²³,Tsujimoto Yasushi¹,Honda Michitaka⁴,Kondo Tsunenori³,Tanabe Kazunari³,Fukuhara Shunichi¹²,Furukawa Toshi A.⁵

Affiliation:

1. Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

2. Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima 960-1295, Japan

3. Department of Urology, Tokyo Women's Medical University, Tokyo 162-8666, Japan

4. Department of Surgery, Southern TOHOKU Research Institute for Neuroscience, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan

5. Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study;European Journal of Cancer;2023-03

2. Biologic Reconstruction With a Motorized Intramedullary Bone Transport Nail After Tumor Resection;Journal of Orthopaedic Trauma;2021-10

3. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study;Journal of Bone and Mineral Metabolism;2021-03-11

4. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?;Translational Oncology;2020-02

5. Clinical benefit of early treatment with bone‐modifying agents for preventing skeletal‐related events in patients with genitourinary cancer with bone metastasis: A multi‐institutional retrospective study;International Journal of Urology;2019-03-18